Higher vancomycin MIC values (≥1.5 mg/L via Etest) may be associated with vancomycin treatment failure among patients with serious methicillin-resistant Staphylococcus aureus (MRSA) infections. As there were limited similar data for teicoplanin, this retrospective cohort study intended to determine the predictive value of teicoplanin MICs for treatment failure among patients with MRSA bacteraemia.
Introduction
Methicillin-resistant Staphylococcus aureus (MRSA) bacteraemia is associated with a longer length of hospital stay, higher total treatment cost and higher risk of mortality than bacteraemia due to other bacterial pathogens. 1, 2 Vancomycin has been the mainstay for the treatment of serious MRSA infections since the early 1980s, when MRSA emerged as a significant nosocomial pathogen. 3, 4 Vancomycin is now still used widely throughout the world, but most of the vancomycin MIC values among MRSA isolates remain within the susceptibility breakpoint (≤2 mg/L) according to the CLSI criteria in 2011. 5 -7 However, several studies have reported a tendency for a gradual increase in vancomycin MIC values among MRSA isolates. 8 -11 Steinkraus et al. 9 evaluated 662 MRSA blood isolates and found a significant change in Etest of MRSA bacteraemia disclosed that vancomycin had 55.6% treatment success in MRSA bacteraemia with vancomycin MICs ≤0.5 mg/L, whereas vancomycin had only 9.5% effectiveness in cases with vancomycin MICs for MRSA of 1 -2 mg/L. 13 These studies have raised a growing concern for clinicians as to whether vancomycin is still a rational choice for the treatment of serious MRSA infections. 14 Teicoplanin, a glycopeptide currently used for the treatment of potentially serious infections caused by b-lactam-resistant Gram-positive pathogens, is not approved for use in the USA, while in Europe it is as commonly used as vancomycin. It has been thought as effective as vancomycin for the treatment of MRSA bacteraemia. 15 However, there are limited studies evaluating the relationship between teicoplanin MIC values and outcomes among patients with serious MRSA infections. 16, 17 Thus, we conducted a retrospective cohort study to examine MRSA isolates obtained from patients with MRSA bacteraemia over a 13 month period, testing their susceptibility to teicoplanin by Etest w and identifying the breakpoint of teicoplanin MICs influencing treatment outcomes.
Patients and methods

Patients and study design
This retrospective cohort study was conducted at the Chang Gung Memorial Hospital (CGMH)-Linkou, a 3715 bed tertiary-care medical centre in northern Taiwan. This study was approved by a research ethics committee (institutional research board) of CGMH-Linkou (Number: 100-1841B). Through the computer-assisted microbiology laboratory databases, all patients with at least one blood culture positive for MRSA admitted to the hospital between January 2010 and January 2011 were reviewed. Patients with fever or other clinical features suggestive of systemic infection were enrolled. If MRSA had been isolated from blood on multiple occasions in the same patient during the study period, only the first episode was reviewed.
A total of 235 patients were identified and the review of medical records was performed before MIC data were available. The patients' clinical data were collected for analysis, including demographics, dates of admission, comorbidities, clinical presentations, sources of bacteraemia and treatment regimens. Patients who met the following criteria were evaluated for the relationship between teicoplanin MIC values and treatment outcomes: age ≥18 years; receipt of teicoplanin therapy throughout the treatment course or receipt of ,72 h of vancomycin therapy and then teicoplanin for .3 days but maybe not throughout the rest of the course; adequate teicoplanin dosage; no teicoplanin allergy; and the treatment response being able to be determined at the end of therapy. Adequate dosage was defined as that based on the manufacturer's instructions (Sanofi-Aventis, Taiwan). Teicoplanin was given at a loading dose of 6 mg/kg (maximum 400 mg per dose) for three loading doses 12 h apart and then every 24 h, adjusted by the patient's renal function. Treatment response was unable to be determined at the end of therapy if the patient had either of the following: (i) inadequate teicoplanin dosage; or (ii) lost or insufficient medical records. Thus, 134 patients were excluded and only 101 patients were enrolled ( Figure 1) .
The exposure to various risk factors was taken into consideration for analysis only if it had occurred before the development of infection. Patient infection sources were categorized as community acquired, hospital acquired and healthcare associated. Community-acquired bacteraemia was defined as bacteraemia onset at ,48 h of admission without any hospital stay and anti-MRSA therapy within 2 weeks before the onset of bacteraemia. Hospital-acquired bacteraemia was defined as bacteraemia onset at ≥48 h after admission. Healthcare-associated bacteraemia was defined as: (i) the bacteraemia episode was associated with the presence of an invasive device; (ii) a recent history of surgery, hospitalization or dialysis (defined as being performed within 3 months before the onset of infection); or (iii) residence in a long-term care facility within the preceding 12 months. The severity of comorbidities was evaluated by the Charlson comorbidity index for chronic diseases and the Pittsburgh bacteraemia score for acute diseases. Sources of bacteraemia were categorized according to the clinical medical records, images, cultures of body sites and the judgement of the physician in charge. Bacteraemia of unknown primary site means there was no definite source to be found.
Efficacy assessment
Treatment response was assessed on the seventh day after teicoplanin initiation to define a short-term outcome and the day that teicoplanin therapy was completed. Patients' short-term outcomes were evaluated by: (i) the occurrence of shock; (ii) the duration of fever; (iii) the progression of leucocytosis; and (iv) persistent bacteraemia on the seventh day. It was considered an unfavourable short-term outcome if one of the above four criteria was present. Besides mortality, clinical response at the end of therapy was categorized as cure, improvement or failure. Cure was defined as the resolution of clinical signs and symptoms with no requirement for antibiotic therapy and a negative culture report at 
Laboratory methods
S. aureus isolates were identified on the basis of the following properties: aerobic, Gram-positive cocci in clusters on a Gram's stain with a catalasepositive, coagulase-positive and ornithine-negative reaction. 18 The identification of MRSA was done by the detection of oxacillin resistance using a 30 mg cefoxitin disc and Mueller-Hinton agar according to CLSI recommendations. 7 All MRSA blood isolates collected from patients with MRSA bacteraemia were routinely stored at our clinical microbiology laboratory. They were preserved in skimmed milk at 2708C until they were tested. The MRSA blood isolates included in this study were selected from the stocks of our microbiology laboratory and were tested to determine the teicoplanin MIC using Etest w teicoplanin strips (AB Biodisk, Solna, Sweden). The Etest w method was used with an inoculum with a turbidity equivalent to that of a 0.5 McFarland standard, brain heart infusion agar (Oxoid, Basingstoke, UK) and 48 h of incubation at 35-378C. Quality control was performed by testing methicillin-susceptible S. aureus ATCC 29213. The MIC breakpoint for teicoplanin resistance is .2 mg/L, in accordance with EUCAST. 19 
Statistical analysis
Descriptive statistics, including the number of observations, mean and standard deviation, were used to summarize the continuous variables. The frequency and proportion were used to summarize the categorical variables. For the continuous variables, a Student's t-test or a Wilcoxon test was used for the test statistics, depending on the validity of the normality assumption. A x 2 test or a Fisher's exact test was used to test the categorical variables. Multivariate analysis was performed using logistic regression to identify factors that independently and significantly affected the outcome. Variables with a P value ,0.05 in univariate analyses were considered for inclusion in a multivariate model. The SPSS w Statistics package (Version 19; IBM Corporation, Somers, NY, USA) was used as the programming software for the analysis.
Results
A total of 101 patients were enrolled in this study, and 56 of them had a lower teicoplanin MIC (≤1.5 mg/L) for MRSA and 45 had a higher teicoplanin MIC (.1.5 mg/L) for MRSA. These patients were divided into the lower MIC (≤1.5 mg/L) and higher MIC (.1.5 mg/L) groups. A comparison of the demographic characteristics, comorbid conditions, Pittsburgh bacteraemia score and sources of bacteraemia between these two groups is shown in To identify risk factors for unfavourable outcome at the endpoint of teicoplanin therapy, these 101 patients were divided into the favourable and unfavourable outcome groups (Table 3) . Patients with COPD and pneumonia had an unfavourable outcome [P ¼ 0.028 (OR 0.194, 95% CI 0.040-0.951) and 0.022 (OR 0.326, 95% CI 0.121 -0.875), respectively]. In contrast, patients with skin and soft tissue infections were more frequently seen in the favourable outcome group [11 (22%) versus 4 (7.8%); P ¼ 0.045]. Compared with the favourable outcome group, patients with an unfavourable outcome had a higher Pittsburgh bacteraemia score (2.9+2.9 versus 1.2+1.8; P,0.001). Multivariate analysis showed that MIC .1.5 mg/L, higher Pittsburgh bacteraemia score and pneumonia were independent risk factors for unfavourable outcome (Table 4) .
Eleven of 50 patients with a favourable outcome died. Pneumonia accounted for more than half of the causes of mortality (6 patients, 54.5%). Besides, 22 patients received other antimicrobial agents after teicoplanin treatment failure. Sixteen of them (72.7%) received daptomycin with a treatment success rate of 68.75% (11 patients). The other three patients (13.6%) received linezolid and one patient still had a poor outcome. The last three patients (13.6%) received tigecycline, but the treatment failure rate was 100%. Of the 22 patients with teicoplanin treatment failure, 10 (45.5%) had MRSA isolates exhibiting a teicoplanin MIC value .1.5 mg/L.
Discussion
A systematic review in 2009 revealed that there were no significant differences between teicoplanin and vancomycin with regard to clinical failure, microbiological failure, clinical efficacy and outcomes, whereas total adverse events, nephrotoxicity and red man syndrome were significantly less frequent with teicoplanin. 20 Teicoplanin has been used widely in Europe and Taiwan; however, there are limited clinical data to demonstrate the relationship between teicoplanin MIC values and clinical outcomes among patients with serious MRSA infections. In a study conducted by Wilson et al. 16 on the prevalence of teicoplanin resistance among Gram-positive pathogens isolated in the intensive care unit (ICU) and the impact of any resistance on clinical outcome, there was no significant difference in the length of hospital or ICU stay or mortality for patients infected by MRSA with reduced susceptibility to teicoplanin compared with those infected by fully susceptible strains. Charlesworth et al. 21 Chang et al.
stated that a higher MIC, as found by Etest w or agar incorporation, was associated with lower survival.
The Etest w method seemed to be more reliable in predicting treatment outcome than automated Vitek 1. 22 Bland et al. considered that MIC values for invasive MRSA isolates generated by automated machines should be confirmed by manual Etest w to identify MRSA isolates with vancomycin MIC values .1 mg/L, which were frequently associated with poor treatment outcomes or increased mortality rates. Several studies have revealed that vancomycin MIC values .1.5 mg/L were associated with a higher rate of treatment failure and 30 day mortality. 8, 22, 24, 25 Thus, we used the Etest w method and chose the teicoplanin MIC of 1.5 mg/L as the cut-off value, and this study revealed that a lower teicoplanin MIC value (≤1.5 mg/L) was associated with a favourable outcome at the end of teicoplanin therapy and a lower bacteraemia-related mortality rate. Multivariate analysis showed that teicoplanin MIC value .1.5 mg/L, higher Pittsburgh bacteraemia score and bacteraemic pneumonia might lead to an unfavourable outcome. This result is correlated to the findings of Walraven et al., 26 who described that patients There are some limitations to our study. First, this is a retrospective, chart-review study of small sample size that enrolled a limited number of patients with MRSA bacteraemia. Second, a molecular analysis for the hospital epidemiology survey was not performed to identify the specific MRSA strains and clones. MRSA strains with specific resistance genes may have an influence on the MIC values. 27, 28 In conclusion, our study offers preliminary data that the teicoplanin Etest w MIC cut-off value of 1.5 mg/L could be predictive for therapeutic outcomes among patients with teicoplanintreated MRSA bacteraemia. The independent risk factors for unfavourable outcome included a higher teicoplanin MIC value (.1.5 mg/L) for MRSA, a high Pittsburgh bacteraemia score and pneumonia. The true significance of diminished clinical activity of teicoplanin against MRSA needs to be further defined by a large-scale study.
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